Four Female Entrepreneurs in the Pharmaceutical Sector Featured in the 2023 Hurun China Rich List for Women

　　【Pharmaceutical Network Industry DynamicsOn November 14, Hurun Report released the "2023 Hurun Female Entrepreneurs List." The total wealth of the 50 Chinese female entrepreneurs on this year's list amounted to 1.37 trillion yuan, marking an 11% decrease from last year. Kwong Siu Hing, the wife of New World Development founder Henry Fok, topped the list for the first time with a fortune of 72 billion yuan, while former richest woman Yang Huiyan of Country Garden saw her wealth drop by 27 billion yuan to just 48 billion yuan.
 

Notably, according to the author's statistics, at least four female entrepreneurs on the list are primarily involved in the pharmaceuticals industry. They are Zhong Hujuan of Hansoh Pharma, Jian Jun of Aimeike, Zhao Yan of Huaxi International Investment Group, and Guo Meilan of Dongyang Light.
 

　　Among them, Zhong Huijuan, 62, of Hansoh Pharma, has a wealth of 42 billion yuan, a year-on-year decrease of 18%. She ranks 8th, falling by 2 places.Hansoh Pharma, the company in question, is a pharmaceutical firm driven by innovative drugs to boost its performance growth. The company's products are mainly used for treating central nervous system diseases, anti-tumor, anti-infection, diabetes, gastrointestinal, and cardiovascular therapies. The company has established multiple research and development centers globally, committing to introduce more innovative drugs to the global market. In 2022, Hansoh Pharma achieved revenue of 9.382 billion yuan (RMB, same below), representing a year-on-year decrease of 5.6%; net profit was 2.584 billion yuan, down 4.8% year-on-year. The company’s current total market value is 83.423 billion yuan.
 

　　Jane Jun Jian, 60, of Huaxi International Investment Group Co., Ltd., has a wealth of 37.5 billion yuan, a year-on-year decrease of 18%. She ranks 10th, down one place.As a leading player in China's medical aesthetics industry, Aimeike has successfully achieved the industrialization of its series of injectable sodium hyaluronate (hyaluronic acid) products and polydioxanone facial thread implants. The company’s products are mainly applied in the medical aesthetics industry to meet the needs of patients before, during, and after procedures. According to the 2022 annual report, the company achieved revenue of 1.938 billion yuan, representing a year-on-year increase of 33.91%, and net profit attributable to shareholders of listed companies was 1.264 billion yuan, reflecting a year-on-year growth of 31.9%.
 

　　The 57-year-old "Hyaluronic Acid Queen" Zhao Yan from Huaxi International Investment Group Co., Ltd. saw her wealth shrink by 14.5 billion yuan to 35 billion yuan. She ranked 12th, dropping five places.Public information shows that in 1989, Zhao Yan founded Huaxi International Investment Group Co., Ltd., which has now become a diversified group company with cultural and sports industries and health and beauty industries as its core, supported by comprehensive industry investment and equity investment. The group owns more than eighty wholly-owned subsidiaries and investment-controlled or participating companies at home and abroad, with total assets exceeding 100 billion yuan. Huaxi International’s investment areas are extensive, including real estate, cultural and sports industries, pharmaceuticals and health industries, and equity investment.
 

　　Moreover, Guo Meilan, 60, from Dongyang Sunshine, has newly entered the rankings, placing 41st with a fortune of 15.5 billion yuan.Dongyang Light is a company mainly engaged in electronic new materials, biomedicine, and health care. Its pharmaceutical sector primarily involves the research, production, and sales of medicines, covering the development and production from generic drugs to innovative drugs, fromActive Pharmaceutical IngredientsThe industrial chain layout extends to the formulation. Among them, Dongyangguang Pharmaceutical is one of the core enterprises under the Dongyangguang Group, focusing on R&D and production in the pharmaceutical field. The company owns multiple innovative drugs and first-to-market generics with independent intellectual property rights in areas such as anti-infectives, antivirals, cardiovascular, anticancer, and immunomodulatory fields. It is also involved in the R&D and production of biosimilars, while actively promoting the development and market launch of new drugs. According to its 2022 annual report, Dongyangguang's revenue in 2022 was approximately 11.699 billion yuan, a year-on-year decrease of 8.62%; the net profit attributable to shareholders of the listed company was about 1.243 billion yuan, a year-on-year increase of 42.25%.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.